Wednesday, 26 August 2026European Markets

METABOLIC EXPLORER Stock 11.83% Up On Thursday

Loading stream...

(vianews) - the market ended the session with metabolic explorer (metex.pa) jumping 11.83% to €1.08 on thursday while cac 40 rose 0.28% to €7,381.78.

metabolic explorer's last close was €0.96, 80.91% under its 52-week high of €5.05.

about metabolic explorer

metabolic explorer s.a., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. the company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and l-valine. its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. the company was incorporated in 1999 and is based in saint-beauzire, france.

earnings per share

as for profitability, metabolic explorer has a trailing twelve months eps of €-0.78.

volatility

metabolic explorer's last week, last month's, and last quarter's current intraday variation average was a positive 0.95%, a negative 0.73%, and a positive 2.68%.

metabolic explorer's highest amplitude of average volatility was 3.72% (last week), 2.17% (last month), and 2.68% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, metabolic explorer's stock is considered to be oversold (<=20).

revenue growth

year-on-year quarterly revenue growth declined by 26.9%, now sitting on 228.15m for the twelve trailing months.

moving average

metabolic explorer's worth is below its 50-day moving average of €1.15 and way below its 200-day moving average of €1.59.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com